⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14718458 | 0.76 | — | — | |
| SCHEMBL153957 | 0.76 | ATP4A (0.35) | — | |
| SCHEMBL28975284 | 0.75 | KAT2B (0.30) | — | |
| SCHEMBL1436781 | 0.75 | — | — | |
| SCHEMBL4012297 | 0.75 | SLC6A3 (0.31) | — | |
| SCHEMBL4262938 | 0.73 | — | — | |
| SCHEMBL303620 | 0.73 | — | — | |
| SCHEMBL28975293 | 0.72 | SLC6A3 (0.32) | — | |
| SCHEMBL5638768 | 0.72 | — | — | |
| SCHEMBL1797891 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| CN-110713489-A | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9914735-B2 | Heteroaryl Syk inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| EP-3119765-A1 | HETEROARYL SYK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3119772-A1 | HETEROARYL SIK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-1460072-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-09-22 | — | — | EP | disclosed |
| EP-1454907-A1 | Quninazoline and pyridopyrmidine derivatives | Glaxo Group Limited (GB) | 2004-09-08 | — | — | EP | disclosed |
| US-6727256-B1 | 4-AMINOQUINAZOLINE DERIVATIVES AS ANTICARCINOGENIC AGENTS | SMITHKLINE BEECHAM CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-6713485-B2 | ANTIPROLIFERATIVE AGENTS; SIDE EFFECT REDUCTION | SMITHKLINE BEECHAM CORPORATION | 2004-03-30 | — | — | US | disclosed |
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | LEO OSPREY LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| US-20020147205-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| EP-1192151-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001004111-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| EP-1047694-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999035146-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |